中国临床药理学杂志2025，Vol.41Issue(3)：301-305,5.DOI:10.13699/j.cnki.1001-6821.2025.03.001
艾司西酞普兰联合多巴丝肼治疗帕金森病患者的临床研究
Clinical trial of escitalopram combined with levodopa and benserazide hydrochloride in the treatment of patients with Parkinson's disease
摘要
Abstract
Objective To observe the clinical efficacy and safety of escitalopram oxalate tablets combined with levodopa and benserazide hydrochloride tablets in the treatment of patients with Parkinson's disease.Methods The patients with Parkinson's disease were randomly divided into control group and treatment group.The control group received levodopa and benserazide hydrochloride tablets 125 mg per time,tid,orally.On the basis of control group,the treatment group received escitalopram oxalate tablets 10 mg per time,qd,orally.Two groups were treated for 3 months.The clinical efficacy,Montreal cognitive assessment(MoCA)scores,Hamilton depression rating scale(HAMD)scores,unified Parkinson's disease rating scale(UPDRS)scores,the levels of interleukin-6(IL-6),tumor necrosis factor-alpha(TNF-α)and nerve growth factor(NGF),and safety were compared between two groups.Results Treatment group was enrolled 116 cases,4 cases dropped out,and 112 cases were finally included in the statistical analysis.Control group was enrolled 116 cases,2 cases dropped out,and 114 cases were finally included in the statistical analysis.After treatment,the total effective rates of treatment and control group were 82.14％(92 cases/112 cases)and 65.79％(75 cases/114 cases),with significant difference(P＜0.05).After treatment,the MoCA scores of treatment and control groups were(24.89±2.87)and(19.58±2.62)points,the HAMD scores were(10.45±1.06)and(15.84±1.49)points,the UPDRS scores were(40.06±5.28)and(47.78±5.52)points,the IL-6 levels were(4.12±0.63)and(6.71±1.13)mg·L-1,the TNF-α levels were(8.71±1.64)and(11.14±2.05)mg·L-1,the NGF levels were(41.56±5.20)and(30.47±4.14)ng·mL-1,respectively.The differences of above indexes were statistically significant between two groups(all P＜0.05).The adverse drug reactions of treatment group were somnolence and nausea/vomiting,while those in control group were nausea/vomiting and constipation.The total incidences of adverse drug reactions in treatment and control groups were 15.18％and 12.28％,without statistically significant difference(P＞0.05).Conclusion Escitalopram oxalate tablets combined with levodopa and benserazide hydrochloride tablets significantly improves clinical efficacy in the treatment of patients with Parkinson's disease,which can significantly ameliorate the inflammatory responses and neurotrophic factor levels,without increasing the incidence of adverse drug reactions.关键词
草酸艾司西酞普兰片/多巴丝肼片/帕金森病/认知功能/神经营养因子/安全性评价Key words
escitalopram oxalate tablet/levodopa and benserazide hydrochloride tablet/Parkinson's disease/cognitive function/neurotrophic factor/safety evaluation分类
医药卫生引用本文复制引用
郭莞莹,林熙汶,李辙,赵楠,舒可..艾司西酞普兰联合多巴丝肼治疗帕金森病患者的临床研究[J].中国临床药理学杂志,2025,41(3):301-305,5.基金项目
云南省科技厅科技计划基金资助项目(202301AY070001-286) （202301AY070001-286）
